Margarida Matias

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

Neutrophil-to-Lymphocyte Ratio Predicts Cerebral Edema and Clinical Worsening Early After Reperfusion Therapy in Stroke

Daniela Ferro, Margarida Matias, Joana Neto et al. · Stroke · 2021 · 128 citations · Full text

Medicine, Neurology, Neurosurgery +16

Fatigue and physical activity in cancer survivors: A cross‐sectional population‐based study

Margarida Matias, Giulia Baciarello, Mohamed Neji et al. · Cancer Medicine · 2019 · 45 citations · Full text

Education, Oncology, Breast Oncology +8

Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre

Margarida Matias, Gwénaël Le Teuff, Laurence Albigès et al. · European Journal of Cancer · 2017 · 27 citations

Medicine, Oncology, Pharmacology +14

In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?

Sandrine Aspeslagh, Margarida Matias, Virginia Palomar Coloma et al. · European Journal of Cancer · 2017 · 23 citations

Life Sciences, Immunology, Oncology +16